Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com

Articles

Addressing Intolerance and Resistance to BTK Inhibition Is Next Frontier in CLL Drug Development

November 9th 2022

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs for patients with chronic lymphocytic leukemia.

Inroads to Targeting HER2-Mutant Lung Cancer Begin Taking Shape

October 20th 2022

Targeted treatment options for patients with HER2-mutant non–small cell lung cancer have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic.

Experts Navigate the New World of HER2-Positive Metastatic Breast Cancer

October 19th 2022

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

An Influx of Data Expands Options, Improves Treatment for Bladder Cancer

October 18th 2022

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

Durvalumab Plus Standard-of-Care Chemotherapy Shakes Up First-line Care in Advanced Biliary Tract Cancers

October 17th 2022

Do-Youn Oh, MD, PhD, highlights the nuances of the TOPAZ-1 trial data that signal new pathways forward for investigative efforts in advanced biliary tract cancers.

Novel Interventions May Reduce Phlebotomy Use in Patients With Polycythemia Vera

October 7th 2022

Patients with polycythemia vera, a myeloproliferative neoplasm associated with JAK2 mutations and overproduction of red blood cells, often require regular therapeutic phlebotomies to avoid thrombosis.

Pan-FGFR Inhibitor Seeks to Overcome Resistance Hurdles in Cholangiocarcinoma and Urothelial Carcinoma

October 3rd 2022

Early sensitivity to FGFR inhibition has improved outcomes for patients across tumor histologies; however, kinase domain mutations limit extended efficacy for select patients including those with intrahepatic cholangiocarcinoma or urothelial cancer.

Duvelisib Loses Support for CLL/SLL Indication Following ODAC Meeting

September 23rd 2022

In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the final overall survival data submitted did not demonstrate a strong enough benefit-risk ratio for duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies.

Clinical Trials Aim to Bring Zenocutuzumab to Patients with NRG1+ Cancers

September 22nd 2022

Blocking ligand interaction of HER2 and HER3 in patients with NRG1 fusion–positive tumors has demonstrated a clinically feasible avenue to improve outcomes with the novel agent zenocutuzumab.

Immunotherapy Drives First-line Systemic Treatment for Advanced HCC

September 19th 2022

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.

Belzutifan Plus Cabozantinib Elicits High Response Rate in Treatment-Naïve Advanced Clear Cell RCC

September 12th 2022

Belzutifan plus cabozantinib was well tolerated and demonstrated promising antitumor activity in patients with treatment-naïve advanced clear cell renal cell carcinoma.

ReFocus Validates RLY-4008 As Active Agent for FGFR2+ Cholangiocarcinoma

September 11th 2022

High response rates and encouraging durability support RLY-4008 as a transformative treatment option for patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Trastuzumab Deruxtecan Maintains Clinical Benefit in Metastatic Gastric/GEJ Cancer

September 10th 2022

Trastuzumab deruxtecan continued to demonstrate a clinical benefit and tolerable safety profile for patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen.

First-line Dalpiciclib Significantly Improves PFS Outcomes for Patients With HR+/HER2– Advanced Breast Cancer

September 9th 2022

The combination of the CDK4/6 inhibitor dalpiciclib plus letrozole or anastrozole reduced the risk of disease progression by 49% vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

Real-World Data Highlight Efficacy of Ide-cel in Patients With Relapsed/Refractory Multiple Myeloma

September 6th 2022

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Investigative Approaches Seek to Enhance Outcomes for Patients With CDK12-Mutant mCRPC

September 3rd 2022

DNA damage homologous recombination repair genotypic variants are not created equal.

Biomarker-Directed Therapy in Multiple Myeloma Signals the Future of the Field

September 1st 2022

Shaji Kumar, MD, and Jonathan Kaufman, MD, review the advances with translocations such as t(11;14), treating practices, and emerging markers in multiple myeloma.

Bispecific Antibody ABBV-383 Looks to Fill Unmet Need in Heavily Pretreated Multiple Myeloma

August 28th 2022

Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.

Dual Checkpoint Blockade Holds Promise as Long-term Treatment Option in NSCLC

August 19th 2022

Stephen V. Liu, MD and Neal E. Ready, MD, PhD, discuss the new data with nivolumab plus ipilimumab in treatment-naïve NSCLC and provide commentary on treatment considerations for patients who are eligible to receive these regimens.

Long-term Data for CDK4/6 Inhibitors Solidify Role in Firstline HR+/HER2- Breast Cancer

August 17th 2022

CDK4/6 inhibitors have carved out a substantial role in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer.